NATCO Pharma Limited (NATCOPHARM.NS)

INR 1473.0

(1.89%)

Market Cap (In INR)

263.82 Billion

Revenue (In INR)

40.02 Billion

Net Income (In INR)

13.88 Billion

Avg. Volume

1.04 Million

Currency
INR
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
755.0-1639.0
PE
-
EPS
-
Beta Value
0.519
ISIN
INE987B01026
CUSIP
Y6211C157
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Rajeev Nannapaneni
Employee Count
-
Website
https://www.natcopharma.co.in
Ipo Date
1996-01-01
Details
NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, ovary, etc.; and APIs in various categories, such as oncology, central nervous system, pain management, and CV care. The company also offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina and CHF. The company markets its products in approximately 40 countries, including India, the United States, and internationally. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.